ArticleMediterranean journal of rheumatology2026
Knowledge, Attitudes, and Clinical Experience with Cannabinoid Therapies: A Cross-Sectional Survey of Rheumatologists.
Article in Mediterranean journal of rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: In Morocco, cannabinoid therapies have recently been legalised. This study aimed to explore the knowledge, attitudes, and perceptions of Moroccan rheumatologists toward these emerging treatments. Methods: A pretested online questionnaire was distributed via email to all members of the Moroccan Society of Rheumatology. The survey assessed participants' knowledge, prescribing confidence, perceived risks, safety precautions, and barriers to the use of cannabinoid therapies. Results: Of the 400 rheumatologists contacted, 126 responded (response rate: 32%). Among them, 59.5% reported confidence in their knowledge of cannabinoid therapies. A total of 80.6% of respondents believed that pharmacological cannabinoids may have a role in managing rheumatic diseases, while 9.7% declared that there is currently no therapeutic role for cannabinoids in rheumatology. Only 7.1% had recommended a therapeutic trial, and 52.8% expressed concern that the use of cannabinoids may cause patients to discontinue effective standard treatments. Fibromyalgia was the most frequently cited indication (85.7%). The main barriers to prescribing cannabinoid therapies were concerns about a history or risk of substance abuse (79.2%) and patient non-compliance with medical advice (79.2%). Conclusion: This finding highlights hesitation and caution toward these emerging treatments in Morocco. There is a clear need for evidence-based guidance to support rheumatologists in clinical decision-making concerning cannabinoids.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.